SCHEMBL31378802

SCHEMBL31378802

CN(C)C1CCC(Oc2ccc(N)cc2)CC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 6/20 0.39
TSHR P16473 2/20 0.39
BCL2A1 Q16548 1/20 0.39
MAPK1 P28482 2/20 0.39
PTPN1 P18031 1/20 0.39
PARP10 Q53GL7 1/20 0.39
HRH3 Q9Y5N1 2/20 0.38
ALDH1A1 P00352 5/20 0.38
CYP3A4 P08684 3/20 0.38
IRAK4 Q9NWZ3 3/20 0.36
TEAD4 Q15561 1/20 0.35
HRH1 P35367 1/20 0.35
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
TP53 P04637 1/20 0.34
ALOX15 P16050 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31378855 0.87 TDP1 (0.40) TDP1TSHRBCL2A1MAPK1ALDH1A1
SCHEMBL20273930 0.85 BCL2A1 (0.39) BCL2A1PTPN1PARP10HRH3IRAK4
SCHEMBL20273869 0.84 ACACB (0.42) BCL2A1HRH3IRAK4
SCHEMBL6903727 0.84 TDP1 (0.50) TDP1TSHRMAPK1PTPN1PARP10
SCHEMBL8314928 0.84 TDP1 (0.50) TDP1TSHRMAPK1PTPN1PARP10
SCHEMBL22855683 0.83 HRH1 (0.53) BCL2A1HRH3HRH1
SCHEMBL18291349 0.80 CYP4F2 (0.43) BCL2A1HRH3CYP3A4IRAK4CYP4F2
SCHEMBL18291367 0.80 CYP4F2 (0.43) BCL2A1HRH3CYP3A4IRAK4CYP4F2
SCHEMBL19127643 0.80 BCL2A1 (0.36) BCL2A1PTPN1PARP10HRH3IRAK4
SCHEMBL12056318 0.79 MCHR1 (0.44) TDP1TSHRMAPK1PTPN1PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-05-29 US disclosed
WO-2025030163-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE IGF1R, TRHR, TSHR TDP1 806/4885TSHR 3/4885BCL2A1 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.